Tirzepatide Significantly Reduces Weight in Patients with OSA
New analysis from SURMOUNT-1 support the use of GLP-1/GIP agonist tirzepatide to reduce weight in patients with OSA and obesity/overweight.
Source: hcplive.com
Stay updated with breaking news from Eli Lilly Sponsored. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New analysis from SURMOUNT-1 support the use of GLP-1/GIP agonist tirzepatide to reduce weight in patients with OSA and obesity/overweight.
"Among COVID patients who were already critically ill on a mechanical ventilator, adding baricitinib to usual care (steroids) saved lives."